null (n=9,901)
null
null
Effect estimate: RR 0.88 (95% CI null)
Absolute Event Rate: 12% vs 13.4%
p-value: p=null
May support dulaglutide in T2D CV prevention; leaves open optimal sequencing and real-world durability.
The article does not contain abstract.
No takes yet. Share an insight, caveat, or question.
Ray et al. (2019) conducted a null in Type 2 Diabetes Mellitus (T2DM) (n=9,901). Dulaglutide vs. Placebo was evaluated on Three-point major adverse cardiac events (MACE) (RR 0.88, 95% CI null, p=null).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: